ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)

Market Cap	2.74B +30.5%
Revenue (ttm)	849.26M +1.6%
Net Income	20.36M -75.5%
EPS	0.08 -75.7%
Shares Out	256.11M
PE Ratio	127.97
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,273,320
Average Volume	14,537,113
Open	10.58
Previous Close	10.57
Day's Range	10.49 - 10.68
52-Week Range	7.44 - 14.23
Beta	0.34
RSI	50.30
Earnings Date	Apr 28, 2026

About SHE:300254

ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, commerce, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, Ebastine tablets, Tamsulosin hydrochloride sustained release capsule...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 1,196
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300254

Financial Performance

In 2024, SHE:300254's revenue was 846.61 million, an increase of 5.92% compared to the previous year's 799.31 million. Earnings were 42.19 million, an increase of 67.45%.